// App-Quantinova.ai

9543 : Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children-s Oncology Group (COG) study AALL07P4.

Researchers

Presenter

  • Anne L. Angiolillo

Principal Investigators

  • Reuven J. Schore

  • Gregory H. Reaman

  • Naomi Joan Winick

  • Meenakshi Devidas

  • Hao W. Zheng

  • Charlotte Wood

  • Ashley R. Lane

  • Elizabeth A. Raetz

  • William L. Carroll

  • Stephen Hunger

Medical Centers

  • Children's Oncology Group, Gainesville, FL

  • New York University Medical Center, New York City, NY

  • University of Colorado Cancer Center, Aurora, CO

  • Center for Cancer and Blood Disorders, Childrens Medical Center Dallas, Dallas, TX

  • Children's Natl Medcl Ctr, Washington, DC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Methotrexate

  • Asparaginase

  • Prednisone

  • EZN-2285

Outcome

  • N/A

Study Design

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved